Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 81

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 81
---
 month and year. At the direction of the
Board, to assist the analysis and decision of the Board with respect to whether to approve the Company’s entry into the Agreement and consummation of the transactions contemplated by the Agreement, the Company’s management prepared the
Dissolution Analysis, a financial analysis of the present value per Share that might be realized in a liquidation as an alternative to pursuing the transactions contemplated by the Agreement. The Dissolution Analysis was also provided to Leerink
Partners in connection with the rendering of its opinion to the Company’s Board and in performing its financial analysis as described below in the section captioned “—Opinion of Leerink Partners.”

46

The following table summarizes the Dissolution Analysis:

| (Amounts in USD millions)                                                          |     |   |       |
|:-----------------------------------------------------------------------------------|:----|:--|------:|
| Cash and cash equivalents, net of payables as of November 30, 2025                 |     | $ | 108.0 |
| Estimated closing transaction expenses in December 2025                            |     |   |  18.8 |
| Estimated remaining administrative and liquidation costs through December 31, 2027 |     |   |   9.1 |
| Estimated cash available for distribution as of December 31, 2025                  |     | $ |  80.1 |
| Estimated initial cash distribution to Shareholders as of December 31, 2025        |     |   |  55.1 |
| Estimated claims process holdback released to Shareholders as of March 31, 2026    |     |   |    18 |
| Estimated final cash distribution to Shareholders as of December 31, 2027          |     | $ |   2.5 |

The Company does not intend to update or otherwise revise the Dissolution Analysis to reflect circumstances existing after the date when prepared or to reflect the occurrence of future events, even if any or all the estimates and assumptions underlying the Dissolution Analysis are no longer appropriate, except as required by law. Accordingly, the inclusion of the Dissolution Analysis in this Circular and Proxy Statement should not be regarded as an indication that the Company or anyone who received the Dissolution Analysis then considered, or now considers, the Dissolution Analysis to be necessarily predictive of actual future events, and this information should not be relied upon as such. These considerations should be considered in evaluating the Dissolution Analysis, which was prepared as of an earlier date.